Thymalfasin (thymosin-alpha 1) is an immunomodulating agent able to enhance the Thl immune response.
In vitro: conjugation of thymalfasin (Tα1) with iRGD preserves the immunomodulatory activity of the drug by increasing the proliferation of mouse spleen lymphocytes. Further, compared with Tα1 treatment, Tα1-iRGD treatment of MCF-7 cells considerably increases the number of cells undergoing apoptosis, resulting in a dose-dependent inhibition of cancer cell growth.
In Vivo: Thymalfasin has been shown to have efficacy in multiple experimental models of immune dysfunction, mainly, infectious diseases such as hepatitis (woodchuck) and influenza (mouse), and cancer such as melanoma (mouse) and colorectal carcinoma (rat) where thymalfasin has shown antitumor effects.
Related Prodcuts:
Abaloparatide; Tetracosactide; Thymalfasin; Thymosin beta 4; Triptorelin; Triptorelin Acetate; Vapreotide; Vasopressin; Ziconotide Acetate; Antide; Protirelin; Teduglutide; Eledoisin; Aviptadil; Teriparatide acetate